Contact Us
Drug Search Results
More Filters [+]

Eptacog alfa

Alternative Names: Eptacog alfa, eptacog alfa (activated), TQG-203, TQG203, TQG 203
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Novo Nordisk is developing eptacog alfa as a treatment for hemophilia A with inhibitor and hemophilia B with inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04768699)

Mechanisms of Action: FVIIa Replacer

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Egypt | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Lebanon | Malaysia | Mexico | Netherlands | Pakistan | Philippines | Poland | Portugal | Russia | Slovakia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eptacog alfa

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2019-002854-22

P3

Active, not recruiting

Unknown

2021-03-04

Recent News Events

Date

Type

Title

12/01/2024

PubMed

 Role of recombinant factor VIIa in the clinical management of severe postpartum hemorrhage: consensus among European experts.

05/01/2024

PubMed

 Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.

04/03/2024

PubMed

 Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies.

10/03/2023

News Article

 [2023-2031] Telco Customer Experience Management Market Demand and Future Scope with Top Key Players

04/11/2022

News Article

 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market by Product Type and Application - Share, Size, Growth, Opportunity and Forecast Till 2022-2031

04/07/2022

News Article

 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market by Product Type and Application - Share, Size, Growth, Opportunity and Forecast Till 2022-2031

04/27/2021

News Article

 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size 2021-Top Companies, Growth Rate, Trends, Product Profiles, Development Plans and Demand Status Forecast to 2025

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions